Association of Single Nucleotide Polymorphisms in SOD2, XRCC1 and XRCC3 with Susceptibility for the Development of Adverse Effects Resulting from Radiotherapy for Prostate Cancer

Abstract Burri, R. J., Stock, R. G., Cesaretti, J. A., Atencio, D. P., Peters, S., Peters, C. A., Fan, G., Stone, N. N., Ostrer, H. and Rosenstein, B. S. Association of Single Nucleotide Polymorphisms in SOD2, XRCC1 and XRCC3 with Susceptibility for the Development of Adverse Effects Resulting from Radiotherapy for Prostate Cancer. Radiat. Res. 170, 49–59 (2008). The objective of this study was to determine whether an association exists between certain single nucleotide polymorphisms (SNPs), which have previously been linked with adverse normal tissue effects resulting from radiotherapy, and the development of radiation injury resulting from radiotherapy for prostate cancer. A total of 135 consecutive patients with clinically localized prostate cancer and a minimum of 1 year of follow-up who had been treated with radiation therapy, either brachytherapy alone or in combination with external-beam radiotherapy, with or without hormone therapy, were genotyped for SNPs in SOD2, XRCC1 and XRCC3. Three common late tissue toxicities were investigated: late rectal bleeding, urinary morbidity, and erectile dysfunction. Patients with the XRCC1 rs25489 G/A (Arg280His) genotype were more likely to develop erectile dysfunction after irradiation than patients who had the G/G genotype (67% compared to 24%; P = 0.048). In addition, patients who had the SOD2 rs4880 T/C (Val16Ala) genotype exhibited a significant increase in grade 2 late rectal bleeding compared to patients who had either the C/C or T/T genotype for this SNP (8% compared to 0%; P = 0.02). Finally, patients with the combination of the SOD2 rs4880 C/T genotype and XRCC3 rs861539 T/C (Thr241Met) genotype experienced a significant increase in grade 2 late rectal bleeding compared to patients without this particular genotypic arrangement (14% compared to 1%; P = 0.002). These results suggest that SNPs in the SOD2, XRCC1 and XRCC3 genes are associated with the development of late radiation injury in patients treated with radiation therapy for prostate adenocarcinoma.

[1]  Margaret R Karagas,et al.  Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. , 2006, Carcinogenesis.

[2]  N. Russell,et al.  Polymorphisms in Genes Involved in Homologous Recombination Repair Interact to Increase the Risk of Developing Acute Myeloid Leukemia , 2004, Clinical Cancer Research.

[3]  Alexandra L Hanlon,et al.  Prostate cancer radiotherapy dose response: an update of the fox chase experience. , 2004, The Journal of urology.

[4]  H. Ostrer,et al.  TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[5]  Q. Wei,et al.  X‐ray repair cross‐complementing group 1 (XRCC1) single‐nucleotide polymorphisms and the risk of salivary gland carcinomas , 2007, Cancer.

[6]  E. Mark,et al.  Polymorphisms in the Dna Repair Genes Xrcc1 and Ercc2 and Biomarkers of Dna Damage in Human Blood Mononuclear Cells Cross-complementing Group 1) than in 399arg/arg Carriers of Breaks following Base Excision Repair (ber) Resulting From , 2022 .

[7]  H. Mohrenweiser,et al.  Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. , 2001, Carcinogenesis.

[8]  Y. Nakanishi,et al.  Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. , 2006, Lung cancer.

[9]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[10]  B. Ponder,et al.  Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Stock,et al.  Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. , 2001, International journal of radiation oncology, biology, physics.

[12]  Sambasivarao Damaraju,et al.  Association of DNA Repair and Steroid Metabolism Gene Polymorphisms with Clinical Late Toxicity in Patients Treated with Conformal Radiotherapy for Prostate Cancer , 2006, Clinical Cancer Research.

[13]  M. Spitz,et al.  Genetic polymorphisms in DNA base‐excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck , 2007, Cancer.

[14]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial , 2003 .

[15]  G. Matullo,et al.  Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study. , 2006, Mutation research.

[16]  H. Kal,et al.  HOW LOW IS THE / RATIO FOR PROSTATE CANCER? , 2003 .

[17]  David J Brenner,et al.  Hypofractionation for prostate cancer radiotherapy--what are the issues? , 2003, International journal of radiation oncology, biology, physics.

[18]  E. Halasová,et al.  Chromosomal damage and polymorphisms of DNA repair genes XRCC1 and XRCC3 in workers exposed to chromium. , 2008, Neuro endocrinology letters.

[19]  P. Scardino,et al.  Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). , 2005, Urology.

[20]  F. B. Sørensen,et al.  Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATMndash; a study based on DNA from formalin fixed paraffin embedded tissue samples , 2006, International journal of radiation biology.

[21]  R. Stock,et al.  Effect of low dose‐rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at ≥ 7 years of follow‐up , 2007, BJU international.

[22]  R. Stock,et al.  A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. , 1995, International journal of radiation oncology, biology, physics.

[23]  U. Vogel,et al.  XRCC3 polymorphisms and risk of lung cancer. , 2004, Cancer letters.

[24]  Barry S Rosenstein,et al.  Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. , 2005, International journal of radiation oncology, biology, physics.

[25]  J. Chang-Claude,et al.  Genetic Polymorphisms in the DNA Double-Strand Break Repair Genes XRCC3, XRCC2, and NBS1 Are Not Associated with Acute Side Effects of Radiotherapy in Breast Cancer Patients , 2006, Cancer Epidemiology Biomarkers & Prevention.

[26]  N. Al-Rajhi,et al.  Radiosensitivity of human fibroblasts is associated with amino acid substitution variants in susceptible genes and correlates with the number of risk alleles. , 2007, International journal of radiation oncology, biology, physics.

[27]  Yun-Chul Hong,et al.  Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer , 2005, International journal of cancer.

[28]  Peter Boyle,et al.  Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma , 2007, Human Genetics.

[29]  M. Olivier.  A haplotype map of the human genome. , 2003, Nature.

[30]  C. Reddy,et al.  Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy , 2003 .

[31]  Nicklas Raun Jacobsen,et al.  No association between the DNA repair gene XRCC3 T241M polymorphism and risk of skin cancer and breast cancer. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[32]  Michael J. Zelefsky,et al.  High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. , 2002, International journal of radiation oncology, biology, physics.

[33]  R. Stock,et al.  Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. , 2001, The Journal of urology.

[34]  R. Stock,et al.  ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[35]  Jeremy M. Stark,et al.  Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks , 2002, Oncogene.

[36]  Christopher A Peters,et al.  A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. , 2007, International journal of radiation oncology, biology, physics.

[37]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[38]  H. Chung,et al.  XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. , 2006, Gynecologic oncology.

[39]  Jack A. Taylor,et al.  DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer , 2006, Molecular carcinogenesis.

[40]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[41]  D J Brenner,et al.  Fractionation and protraction for radiotherapy of prostate carcinoma. , 1999, International journal of radiation oncology, biology, physics.

[42]  K. Miyagawa,et al.  XRCC3 deficiency results in a defect in recombination and increased endoreduplication in human cells , 2004, The EMBO journal.

[43]  Hongbing Shen,et al.  XRCC1 Polymorphisms and Cancer Risk: A Meta-analysis of 38 Case-Control Studies , 2005, Cancer Epidemiology Biomarkers & Prevention.

[44]  H. Thierens,et al.  Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. , 2005, International journal of radiation oncology, biology, physics.

[45]  Michael Baumann,et al.  Towards genetic prediction of radiation responses: ESTRO's GENEPI project. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[46]  D. Pessayre,et al.  The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability , 2005, Pharmacogenetics and genomics.

[47]  J. Overgaard,et al.  Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[48]  D. Pessayre,et al.  The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. , 2003, Pharmacogenetics.

[49]  J. Chang-Claude,et al.  Association between Polymorphisms in the DNARepair Genes , XRCC 1 , APE 1 , and XPD and Acute Side Effects of Radiotherapy in Breast Cancer Patients , 2005 .

[50]  R. Stock,et al.  A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.

[51]  N. Rothman,et al.  Polymorphisms in DNA repair genes and risk of non-Hodgkin’s lymphoma in New South Wales, Australia , 2007, Haematologica.

[52]  So-Yeon Park,et al.  The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[53]  M. Plumb,et al.  The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes , 2007, British Journal of Cancer.

[54]  Ulla Vogel,et al.  The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population. , 2007, Lung cancer.

[55]  L. Anderson,et al.  Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .

[56]  J. Chang-Claude,et al.  Association between Polymorphisms in the DNA Repair Genes, XRCC1, APE1, and XPD and Acute Side Effects of Radiotherapy in Breast Cancer Patients , 2005, Clinical Cancer Research.

[57]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[58]  J. Lamerdin,et al.  XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. , 1998, Molecular cell.

[59]  H. Thierens,et al.  Microsatellite Polymorphisms in DNA Repair Genes XRCC1, XRCC3 and XRCC5 in Patients with Gynecological Tumors: Association with Late Clinical Radiosensitivity and Cancer Incidence , 2005, Radiation research.

[60]  J. Cerhan,et al.  Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. , 2006, Carcinogenesis.

[61]  S. Lippman,et al.  Molecular signatures of lung cancer--toward personalized therapy. , 2007, The New England journal of medicine.

[62]  C. Reddy,et al.  Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  W. Butler,et al.  Erectile function after permanent prostate brachytherapy. , 2002, International journal of radiation oncology, biology, physics.

[64]  R. Stock,et al.  Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. , 2006, International journal of radiation oncology, biology, physics.

[65]  David J Brenner,et al.  What hypofractionated protocols should be tested for prostate cancer? , 2002, International journal of radiation oncology, biology, physics.

[66]  W. Butler,et al.  Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. , 2002, International journal of radiation oncology, biology, physics.

[67]  A. Harris,et al.  A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. , 2000, Cancer research.

[68]  M. Fernet,et al.  Genetic biomarkers of therapeutic radiation sensitivity. , 2004, DNA repair.

[69]  Marek Kimmel,et al.  Haplotype and linkage disequilibrium architecture for human cancer-associated genes. , 2002, Genome research.

[70]  R. Stock,et al.  Screening breast cancer patients for ATM mutations and polymorphisms by using denaturing high‐performance liquid chromatography , 2001, Environmental and molecular mutagenesis.

[71]  D. Brenner,et al.  A preliminary report: frequency of A-T heterozygotes among prostate cancer patients with severe late responses to radiation therapy. , 1998, The cancer journal from Scientific American.

[72]  Paul D.P. Pharoah,et al.  Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. , 2007, Journal of the National Cancer Institute.

[73]  C. Wilding,et al.  Influence of polymorphisms at loci encoding DNA repair proteins on cancer susceptibility and G2 chromosomal radiosensitivity , 2007, Environmental and molecular mutagenesis.

[74]  J. Rzeszowska-Wolny,et al.  Influence of Polymorphisms in DNA Repair Genes XPD, XRCC1 and MGMT on DNA Damage Induced by Gamma Radiation and its Repair in Lymphocytes In Vitro , 2005, Radiation research.

[75]  S Rozen,et al.  Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.

[76]  M. Fenech,et al.  hOGG1(326), XRCC1(399) and XRCC3(241) polymorphisms influence micronucleus frequencies in human lymphocytes in vivo. , 2007, Mutagenesis.

[77]  J. Nickoloff,et al.  XRCC3 controls the fidelity of homologous recombination: roles for XRCC3 in late stages of recombination. , 2002, Molecular cell.

[78]  Paul D P Pharoah,et al.  Variants in DNA double-strand break repair genes and breast cancer susceptibility. , 2002, Human molecular genetics.

[79]  J. Yarnold,et al.  TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[80]  Jun Nakamura,et al.  The Arg280His polymorphism in X-ray repair cross-complementing gene 1 impairs DNA repair ability. , 2005, Mutation research.

[81]  R. Stock,et al.  Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. , 1996, International journal of radiation oncology, biology, physics.

[82]  M. Olivier.  A haplotype map of the human genome , 2003, Nature.

[83]  N. Malats,et al.  Genetic variation in the base excision repair pathway and bladder cancer risk , 2007, Human Genetics.

[84]  Juni Palmgren,et al.  Variation in DNA Repair Genes ERCC2, XRCC1, and XRCC3 and Risk of Follicular Lymphoma , 2006, Cancer Epidemiology Biomarkers & Prevention.

[85]  D. Brenner,et al.  Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue , 2002 .